Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

Hye Jin Kang, Won Seog Kim, Seok Jin Kim, Je Jung Lee, Deok Hwan Yang, Jin Seok Kim, Se Ryeon Lee, Gyeong Won Lee, Hyo Jung Kim, Ho Young Kim, Sung Yong Oh, Hugh Chul Kim, Hyeon Seok Eom, Jooseop Chung, Jinny Park, Cheolwon Suh, Baek Yeol Ryoo

Research output: Contribution to journalArticlepeer-review

33 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study'. Together they form a unique fingerprint.

Medicine & Life Sciences